Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

The article is available online at http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2007-0 6- 095646v1. The analysis will also be published in a future print edition of Blood.

About PNH

PNH is an acquired genetic blood disorder defined by hemolysis, in which patients' red blood cells are destroyed by complement, a component of the body's immune system. PNH is a rare disease that affects an estimated 8,000 to 10,000 people in North America and Europe.(13) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's.(3) Approximately ten percent of all patients first develop symptoms at 21 years of age or younger.(2) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years.(4) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis.(13,4)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS).(14,15,16,17) In patients with thrombosis of unknown origin, PNH may be an underlying cause.(2,18)

Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk.(2,18)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commi
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
2. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
3. What patients want: A story of choice, clinical trials & evidence-based medicine
4. Heart patients benefit from digital image network
5. LEDS Bring Relief to Young Cancer Patients
6. CPM Helps Physicians Group Retain Patients with New Kind of House Call
7. Fast and Easy Isolation of PCR-Ready Genomic DNA from Whole Blood
8. Genomic DNA Extraction from Buccal Swabs Using the Perfect gDNA Blood Mini Kit
9. Genomic DNA Extraction from Buffy Coat Using the Perfect gDNA Blood Mini Kit
10. EppendorfPerfect gDNA Blood Mini Kit
11. Higher gDNA Concentrations with the Perfect gDNA Blood Mini Kit by Varying the Final Elution Volume
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 Spartan Bioscience ... Spartan RX CYP2C19 System . It detects CYP2C19 genetic ... cheek swab. , The Spartan RX CYP2C19 System is ... has been approved in Canada. Due to the system’s ... may be used by healthcare professionals such as doctors, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and the one-year ... of high volume High Pressure Processing (HPP) systems. , “We’re ... PackExpo this year, which is where we first announced the ... CEO at Avure. “Sales of the new Avure machine are ... challenges of market demand for higher throughput. We sold our ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... ET, LOS ANGELES, Aug. 31 Signalife, Inc. (Amex:,SGN), Lowell ... update since his matriculation into the Presidency,last month: 1. Dr. ... positions that were producing no revenue whatsoever and no ... Company, in his view. That was done ...
... Aug. 30 Cepheid (Nasdaq:,CPHD) will present at ... the Four Seasons Hotel, Boston, September 5 to ... Senior Vice President, Finance and,Chief Financial Officer, John ... on,September 7. The webcast, along with accompanying ...
... ON, Aug. 30 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... subsidiary, YM BioSciences USA,Inc. ("YM-USA") has been cleared ... initiate a Phase II trial investigating nimotuzumab in ...
Cached Biology Technology:Signalife Provides Corporate Update 2Signalife Provides Corporate Update 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 3YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 4YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 5
(Date:10/29/2014)... 2014 — Cambridge, MA and Hebei, China — BGI ... high quality sequencing of the Jujube genome. Jujube is ... and the Jujube genome is particularly difficult to sequence ... factors. It is the first time that a genome ... study has been recently published in Nature ...
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... novel environment are linked to individual differences in ... completed at the University of Eastern Finland and ... study used novel, long-term observations of individual behaviour ... if behaviours predict the vulnerability to fishing in ... rearing environments. Based on the results, it ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3Fish 'personality' linked to vulnerability to angling 2
... is the primary component of nursery container substrates in ... widely used organic material is prompting researchers to investigate ... James E. Altland and Charles Krause of the USDA ... Development Center was designed to determine if ground switchgrass ...
... statistics buried within patient records or detailed in newspaper ... patterns, allowing the discovery of trends that were previously ... use of interactive maps and graphs, combined with word ... events like the spread of Swine flu," said Frank ...
... the Braunschweiger Helmholtz-Zentrums fr Infektionsforschung (Helmholtz Center for ... bacterial communities are able to support the degradation ... collaboration of thirteen partners from nine countries. Research ... today at the HZI. The significance of this ...
Cached Biology News:Switchgrass proves viable as nursery container substrate 2Switchgrass proves viable as nursery container substrate 3Visualization of geographic patterns may predict spread of disease 2Improving the degradation of toxic hydrocarbons 2
RABBIT ANTI AMPHOTERIN...
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
... by R. Edwards (1996) • ... types of immunoassays, including RIA, ... and on the photoluminescent and ... information is also given on ...
... contains the basic components required for the ... and recombinant Feline IL-10 in cell culture ... materials to run ELISAs on approximately fifteen ... are met: The assay is run ...
Biology Products: